KOREA WHO

Lee Hee-yong is the CEO of G2GBIO.

He focuses on expanding cooperation with global big pharma companies and building patent barriers through securing intellectual property rights.

He was born on April 4, 1965.

He graduated from the Department of Biochemistry at Yonsei University and earned both his master’s and doctoral degrees in biochemical engineering at KAIST (Korea Advanced Institute of Science and Technology).

He worked as a postdoctoral researcher at the Korea Research Institute of Chemical Technology (KRICT), the College of Pharmacy at the University of Kentucky in the United States, and KAIST. He also served as a senior researcher at Hyundai Pharm and at the Antioxidant Protein Research Center at Paichai University.

He further worked as a research professor at the College of Pharmacy at Wonkwang University.

At Peptron, he spent about 14 years serving as head of the research institute and overseeing business development, before founding G2GBIO in 2017.

He has devoted more than 30 years to the development of sustained-release injectable drugs.

He values honest corporate management and social contribution.

#G2GBIO #LeeHeeyong #biopharma #drugdevelopment #sustainedrelease #bigpharma #patents #KAIST #YonseiUniversity #Peptron #pharmaceuticals